Differentiation and reversal of malignant changes in colon cancer through PPARĪ³ Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Colonic Neoplasms
  • Receptors, Cytoplasmic and Nuclear
  • Thiazolidinediones
  • Transcription Factors

abstract

  • PPARgamma is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPARgamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPARgamma ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.

publication date

  • September 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/2030

PubMed ID

  • 9734398

Additional Document Info

start page

  • 1046

end page

  • 52

volume

  • 4

number

  • 9